Targets › MLLT3
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2029.
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognizes and binds acylated histone H3, with a preference for histone H3 that is crotonylated. Crotonylation marks active promoters and enhancers and confers resistance…. (UniProt, P42568)
Open in Phaseline: the race on MLLT3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | AZD3632 MLLT3 protein-protein interaction inhibitor; targets menin-KMT2A interaction in KMT2A-rear | MLLT3 | Phase 1 | Acute Lymphoblastic Leukaemia | Feb 2029 |
Acute Lymphoblastic Leukaemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.